Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
Clin Obes
; 11(2): e12439, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1015529
ABSTRACT
The aim of the present manuscript is to discuss on potential pros and cons of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as glucose-lowering agents during COVID-19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without diabetes mellitus type 2. Besides being important glucose-lowering agents, GLP-1RAs pose promising anti-inflammatory and anti-obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP-1RAs seem to be potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptide-1 Receptor
/
COVID-19
/
COVID-19 Drug Treatment
/
Hypoglycemic Agents
/
Obesity
Type of study:
Experimental Studies
/
Observational study
Limits:
Humans
Language:
English
Journal:
Clin Obes
Year:
2021
Document Type:
Article
Affiliation country:
Cob.12439
Similar
MEDLINE
...
LILACS
LIS